Table 1 Patient groups by PET/CSF amyloid status

 N (%)

315 (41)

32 (4)

65 (8)

356 (46)

 Sex, male (%)

211 (67)^D

17 (53)

41 (63)

192 (54)^A

 Age, years (mean (SD))

62.8 (7.7)

65.0 (7.7)

62.4 (9.0)

63.7 (7.3)

 Education (median [IQR])

5 [4, 6]

5 [4, 6]

5 [4, 6]

5 [4, 6]

 SCD

136 (43)

10 (31)

20 (31)

28 (8)

 MCI

55 (18)

8 (25)

9 (14)

55 (15)

 AD dementia

28 (9)

11 (34)

17 (26)

253 (71)

 Non-AD dementia

96 (31)

3 (9)

19 (29)

20 (6)

 CSF-PET difference, days (mean (SD))

61 (75)

54 (70)

74 (84)

58 (67)

 CSF Aβ₄₂, pg/mL (median [IQR])

1134 [989, 1275]^BCD

875 [832, 959]^ACD

674 [625, 741]^ABD

615 [537, 688]^ABC

 CSF tau, pg/mL (median [IQR])

277 [207, 375]^BD

468 [324, 716]^AC

287 [174, 501]^BD

609 [403, 845]^AC

 CSF p-tau, pg/mL (median [IQR])

44 [35, 54]^BD

67 [50, 90]^AC

41 [28, 61]^BD

82 [58, 103]^AC

 APOE E4 positivity (%)

84 (28)^BCD

18 (60)^A

32 (52)^A

238 (70)^A

 MMSE (mean (SD))

26 (3)^BD

24 (5)^A

25 (4)

23 (4)^A

 Memory z-score (mean (SD))

− 1.39 (2.27)^BD

− 3.14 (2.73)^A

− 2.20 (2.96)

− 3.34 (2.76)^A

 Language z-score (mean (SD))

− 0.65 (1.29)

− 0.95 (1.48)

− 1.44 (2.27)^C

− 1.03 (1.83)^D

 Attention z-score (mean (SD))

− 0.69 (1.09)^D

− 0.82 (1.08)

− 0.98 (1.02)

− 1.10 (1.21)^A

 Executive z-score (mean (SD))

− 1.01 (1.38)^D

− 1.39 (1.55)

− 1.27 (1.32)

− 1.53 (1.40)^A

 Visuospatial z-score (mean (SD))

−0.34 (1.18)^D

− 1.04 (1.90)

− 0.90 (1.70)

− 1.36 (2.40)^A

 MRI-amyloid difference, days (mean (SD))

16 (50)^C

35 (60)

44 (78)^AD

14 (45)^C

 MTA (median [IQR])

0.5 [0.0, 1.0]^D

0.5 [0.0, 1.0]

0.5 [0.0, 1.8]

1.0 [0.5, 1.5]^A

 PCA (median [IQR])

1.0 [0.0, 1.1]^D

1.0 [1.0, 1.0]

1.0 [0.0, 1.4]^D

1.0 [1.0, 2.0]^AC

 Fazekas (median [IQR])

1.0 [0.0, 1.0]

1.0 [0.8, 1.0]

1.0 [0.0, 2.0]

1.0 [0.0, 1.0]

 Lacune positivity (%)

14 (6)

0 (0)

7 (11)

17 (7)

 Microbleed positivity (%)

31 (13)

4 (15)

4 (7)

54 (21)